相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。COX-2/sEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence
Chen-Yu Zhang et al.
FEBS JOURNAL (2020)
US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States
Rajiv Saran et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice
Chen-Chen Sun et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Inflammatory Targets in Diabetic Nephropathy
Javier Donate-Correa et al.
JOURNAL OF CLINICAL MEDICINE (2020)
A COX-2/sEH dual inhibitor PTUPB ameliorates cecal ligation and puncture-induced sepsis in mice via anti-inflammation and anti-oxidative stress
Yan-Feng Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020
Elliott Lilley et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Nathalie Percie du Sert et al.
PLOS BIOLOGY (2020)
A COX-2/sEH dual inhibitor PTUPB alleviates lipopolysaccharide-induced acute lung injury in mice by inhibiting NLRP3 inflammasome activation
Hui-Hui Yang et al.
THERANOSTICS (2020)
A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice
Md. Abdul Hye Khan et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
Annabelle M. Warren et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2019)
The Impact of Obesity and Type 2 Diabetes on Chronic Liver Disease
Zobair M. Younossi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor
Allison Gartung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Chronic inflammation in the etiology of disease across the life span
David Furman et al.
NATURE MEDICINE (2019)
COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Fuli Wang et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology
Steve P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers
Michael J. Curtis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes
Md Abdul Hye Khan et al.
DIABETOLOGIA (2018)
Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics
John D. Imig
PHARMACOLOGY & THERAPEUTICS (2018)
Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases
Thomas Sonnweber et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Lipid management in patients with chronic kidney disease
Charles J. Ferro et al.
NATURE REVIEWS NEPHROLOGY (2018)
Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells
Hyo Seon Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The metabolic syndrome and chronic kidney disease
Xin Zhang et al.
TRANSLATIONAL RESEARCH (2017)
COX-2/sEH dual inhibitor PTUPB suppresses glioblastoma growth by targeting epidermal growth factor receptor and hyaluronan mediated motility receptor
Junyang Li et al.
ONCOTARGET (2017)
Diabetic Nephropathy: a Tangled Web to Unweave
Corey Magee et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes
Rania Nasrallah et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Longitudinal Changes in Measured Glomerular Filtration Rate, Renal Fibrosis and Biomarkers in a Rat Model of Type 2 Diabetic Nephropathy
Zhi Su et al.
AMERICAN JOURNAL OF NEPHROLOGY (2016)
Nonalcoholic Fatty Liver Disease Pathophysiology and Management
Rotonya M. Carr et al.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA (2016)
Perirenal Fat Promotes Renal Arterial Endothelial Dysfunction in Obese Swine through Tumor Necrosis Factor-α
Shuangtao Ma et al.
JOURNAL OF UROLOGY (2016)
A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat
Md. Abdul Hye Khan et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2016)
Validation of HOMA-IR in a model of insulin-resistance induced by a high-fat diet in Wistar rats
Luciana C. Antunes et al.
ARCHIVES OF ENDOCRINOLOGY METABOLISM (2016)
FT-IR imaging for quantitative determination of liver fat content in non-alcoholic fatty liver
K. Kochan et al.
ANALYST (2015)
Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese rat model of the metabolic syndrome
Eunice Molinar-Toribio et al.
BRITISH JOURNAL OF NUTRITION (2015)
Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice
Clothilde Roche et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2015)
Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice
Todd R. Harris et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2015)
Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets
Stephanie Toth-Manikowski et al.
JOURNAL OF DIABETES RESEARCH (2015)
Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Daria V. Ilatovskaya et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2015)
Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy
Jinu Kim et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat
Md. Abdul Hye Khan et al.
CARDIOVASCULAR DRUGS AND THERAPY (2014)
Molecular mechanisms of diabetic cardiomyopathy
Heiko Bugger et al.
DIABETOLOGIA (2014)
Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis
Guodong Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation
Jinu Kim et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010
Sarah Stark Casagrande et al.
DIABETES CARE (2013)
Gamma aminobutyric acid B and 5-hydroxy tryptamine 2A receptors functional regulation during enhanced liver cell proliferation by GABA and 5-HT chitosan nanoparticles treatment
Joy Shilpa et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension
Jan Neckar et al.
CLINICAL SCIENCE (2012)
Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats
John D. Imig et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2012)
Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy
Daniel Batlle et al.
KIDNEY INTERNATIONAL (2012)
EPOXIDES AND SOLUBLE EPOXIDE HYDROLASE IN CARDIOVASCULAR PHYSIOLOGY
John D. Imig
PHYSIOLOGICAL REVIEWS (2012)
Inhibition of Soluble Epoxide Hydrolase Attenuates High-Fat-Diet-Induced Hepatic Steatosis by Reduced Systemic Inflammatory Status in Mice
Yan Liu et al.
PLOS ONE (2012)
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats
Victor P. Bilan et al.
JOURNAL OF ENDOCRINOLOGY (2011)
Synthesis and Structure-Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase
Sung Hee Hwang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Eicosanoids, β-cell function, and diabetes
Pengcheng Luo et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2011)
Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
John D. Imig et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension
Marlina Manhiani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
An update on cyclooxygenase-2 expression and metabolites in the kidney
Raymond C. Harris
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2008)
Opposite Regulation of Cholesterol Levels by the Phosphatase and Hydrolase Domains of Soluble Epoxide Hydrolase
Ahmed E. EnayetAllah et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor
Raquel Horrillo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier
Jan Michael Williams et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Overexpression of cyclooxygenase-2 predisposes to podocyte injury
Huifang Cheng et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Inflammation and metabolic disorders
Goekhan S. Hotamisligil
NATURE (2006)
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy
SM Grundy
NATURE REVIEWS DRUG DISCOVERY (2006)
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension
JD Imig et al.
HYPERTENSION (2005)
Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats
XY Zhao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Cyclooxygenases, the kidney, and hypertension
HF Cheng et al.
HYPERTENSION (2004)
Rofecoxib decreases renal injury in obese Zucker rats
A Dey et al.
CLINICAL SCIENCE (2004)
Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney
CK Fujihara et al.
KIDNEY INTERNATIONAL (2003)
Experimental hyperlipidemia and the effect of NSAIDs
AP Kourounakis et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2002)
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension
JD Imig et al.
HYPERTENSION (2002)
Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the fa/fa Zucker rat
N Gassler et al.
KIDNEY INTERNATIONAL (2001)
Cardiovascular morbidity and mortality associated with the metabolic syndrome
B Isomaa et al.
DIABETES CARE (2001)
Renal disease in type 2 diabetes
E Ritz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2001)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
C Bombardier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities Study
P Muntner et al.
KIDNEY INTERNATIONAL (2000)
A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats
JL Wang et al.
KIDNEY INTERNATIONAL (2000)
分享论文
